Acuitas Medical: The DOJ Charged This Lab Network With Billing Medicare for Complex Blood Panels Patients Never Requested

Acuitas Medical LLC and its principals faced Department of Justice charges alleging the laboratory network had submitted millions of dollars in fraudulent claims to Medicare for expensive, complex blood test panels — including pharmacogenomics testing and cancer biomarker panels — that patients had not requested, physicians had not ordered, and that had no documented clinical basis in the patients billed. The scheme, as described in the DOJ's charging documents, generated laboratory revenue by running unrequested tests on patient samples obtained through various means and submitting claims to Medicare as though the tests had been ordered as part of the patients' medical care.DOCUMENTED

The Acuitas case was part of a sustained DOJ and HHS enforcement campaign against laboratory billing fraud — a sector that has been among the most productive areas for false claims enforcement in recent years, with the DOJ recovering billions of dollars from laboratory fraud schemes involving unrequested testing, genetic test fraud, and the conversion of routine specimen collection events into vehicles for billing large panels of unrequested tests to government health programs.

How Unrequested Laboratory Testing Fraud Works

Medicare covers laboratory testing that is medically necessary — ordered by a treating physician as part of the patient's medical care based on a clinical indication documented in the medical record. Unrequested laboratory testing fraud bypasses this coverage framework by obtaining patient samples through marketing programs, wellness events, or other means, running extensive and expensive test panels on those samples without any physician order or clinical indication, and submitting claims to Medicare as though the tests had been ordered and were medically necessary. The laboratory collects revenue for tests that had no clinical basis and that Medicare would not have covered had it known the tests were not ordered by a treating physician in the context of actual patient care.REVIEWED

The specific test categories favored in these fraud schemes tend to be expensive and difficult for Medicare to verify as medically necessary on a claim-by-claim basis without clinical context — pharmacogenomics tests that assess how a patient's genetic variants affect drug metabolism, comprehensive cancer biomarker panels, and specialized diagnostic panels with reimbursement rates that are high relative to the cost of running the tests. The combination of high per-test reimbursement and the difficulty of automated medical necessity verification creates the economic opportunity that fraud operators exploit at scale, running large numbers of tests with minimal incremental cost while generating substantial Medicare reimbursement on each claim.DOCUMENTED

Patient Sample Acquisition Schemes

The mechanics of unrequested laboratory testing fraud require a mechanism for obtaining patient samples — blood draws, cheek swabs, or other specimens — that can be submitted to the laboratory for testing and billing. Fraud operations in this space have used several approaches: marketing programs that offer patients free health screenings at community events, arrangements with nursing homes or assisted living facilities that allow the laboratory to draw blood from residents under the guise of routine health monitoring, telemedicine arrangements where a physician nominally orders a test panel for a patient they have never met based on minimal interaction, and arrangements with marketers who receive per-specimen payments for connecting patients with the laboratory. Each approach creates a supply of patient specimens that the laboratory can test and bill as though the testing was physician-ordered and medically necessary.REVIEWED

In the Acuitas Medical case, the DOJ's charging documents described the mechanism through which patient samples were obtained and tests were run without genuine physician orders — a mechanism that the company had designed specifically to generate Medicare-billable laboratory claims at scale. The absence of genuine physician orders for the billed tests, and the absence of clinical documentation in the patients' medical records supporting the medical necessity of the testing, were the evidentiary foundation for the false claims charges. Medicare claims that assert medical necessity for tests that were not ordered and have no clinical basis are false claims on their face, and the volume of such claims documented by the DOJ represented systematic fraud rather than isolated billing errors.

Running a blood test a patient never asked for and billing Medicare for it as though a doctor ordered it is not a laboratory service. It is a billing scheme that uses the patient as a vehicle — and their genetic data and biomarkers as the commodity — to extract money from federal health programs.

Pharmacogenomics Testing Fraud Specifically

Pharmacogenomics tests — which analyze a patient's genetic variants to predict how they will metabolize specific medications — have been a recurring subject of laboratory fraud enforcement because they are expensive, their medical necessity is difficult to verify without clinical context, and aggressive marketers in the space developed schemes to run these tests on patients who had no clinical indication for the testing and no physician relationship with the laboratory. The CMS has implemented prior authorization requirements for certain high-cost pharmacogenomics tests in response to the fraud pattern, but enforcement remains necessary to address fraud in the space that precedes or circumvents these administrative controls.DOCUMENTED

The Acuitas Medical case was one of multiple enforcement actions against laboratory networks operating in the pharmacogenomics fraud space, reflecting the DOJ and HHS-OIG's recognition that the sector had attracted fraud operators who saw the combination of high test reimbursement and weak medical necessity verification as an opportunity for systematic false billing. The enforcement campaign in this area has resulted in multi-billion-dollar recoveries and has included both civil False Claims Act resolutions and criminal prosecutions of laboratory owners and operators who directed the fraudulent billing schemes.

Patient Harm Beyond Financial Loss

Unrequested laboratory testing fraud harms patients beyond the financial harm to Medicare. Patients whose samples are used for unrequested testing may receive test results for which they had no clinical context, were not expecting, and may not have wanted — including genetic information about drug metabolism or cancer biomarkers that patients might have actively chosen not to know. Results generated through the fraud scheme may not be interpreted by a physician who knows the patient's clinical history, may be incorrect due to poor sample handling, and may create anxiety about findings that have no clinical significance for the patient. The patient who becomes an unwitting vehicle for laboratory fraud has been subjected to a form of medical testing without genuine informed consent — a harm that goes beyond the billing fraud to implicate the ethical foundations of the patient-provider relationship that medical testing is supposed to be embedded in.

Have documents relevant to this story? Reach us through our tips channel.